Participant flow

Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer · Source last updated 2026-02-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Palbociclib 125 mg daily and AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestratnt)

   id

   FG000

   title

   Arm A

2. description

   AntiHER2 Therapy (trastuzumab/pertuzumab) q3wks + Endocrine Therapy (letrozole, anastrozole, exemstane OR fulvestrant)

   id

   FG001

   title

   Arm B

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         261

      2. group Id

         FG001

         num Subjects

         257

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         261

      2. group Id

         FG001

         num Subjects

         257

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice